Suppliers and packagers for ec-naprosyn

ec-naprosyn

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Atnahs Pharma Us	EC-NAPROSYN	naproxen	TABLET, DELAYED RELEASE;ORAL	020067	NDA AUTHORIZED GENERIC	Zameer Pharmaceuticals LLC	90096-161-01	100 TABLET, DELAYED RELEASE in 1 BOTTLE (90096-161-01)	2025-08-31

Suppliers for the Pharmaceutical Drug: EC-NAPROSYN

Last updated: July 29, 2025

Introduction

EC-NAPROSYN, the enteric-coated formulation of naproxen, is widely used for its anti-inflammatory, analgesic, and antipyretic properties. As with many established pharmaceutical agents, the supply chain encompasses a network of manufacturers, distributors, and generic producers. Understanding the landscape of suppliers for EC-NAPROSYN is critical for stakeholders, including pharmaceutical companies, healthcare providers, and regulatory authorities, to ensure consistent availability, quality, and compliance.

Overview of EC-NAPROSYN

Naproxen, chemically known as (S)-6-methoxy-2-naphthalenecarboxylic acid, belongs to the nonsteroidal anti-inflammatory drugs (NSAIDs) class. The enteric-coated formulation, EC-NAPROSYN, is designed to release the drug gradually in the intestines, reducing gastrointestinal side effects associated with naproxen. This formulation is approved and marketed in various regions, with multiple suppliers contributing to global distribution.

Major Suppliers and Manufacturers

1. Original Brand Manufacturers

• Bayer AG
  As the original developer, Bayer historically manufactured and marketed Naprosyn, including its EC formulation. Bayer’s global infrastructure ensures consistent supply and high-quality standards. The company’s extensive manufacturing sites are cGMP-compliant, ensuring adherence to regulatory standards globally.

• Sanofi (formerly Sanofi-Aventis)
  Sanofi has historically been involved in manufacturing naproxen-based formulations, including branded versions with enteric coatings. Their manufacturing facilities comply with international standards, and they supply both branded and generic markets.

2. Generic Manufacturers

Several pharmaceutical companies manufacture generic versions of EC-NAPROSYN, often produced in compliance with regulatory authorities such as the FDA (United States), EMA (Europe), and other regional agencies.

• Purdue Pharma
  Known historically for producing various NSAIDs, Purdue Pharma’s generic division supplies enteric-coated naproxen formulations, sometimes under private labels or regional trademarks.

• Aurobindo Pharma
  A leading Indian pharmaceutical manufacturer, Aurobindo produces generic naproxen products, including enteric-coated formulations, exported globally. Their manufacturing adheres to international standards, with FDA approval for several complexes.

• Torrent Pharmaceuticals
  An Indian-based firm, Torrent manufactures naproxen and generic formulations, including enteric-coated tablets, with extensive distribution networks across Asia, Africa, and Latin America.

• Mylan (now part of Viatris)
  Mylan produces generic NSAIDs, including naproxen in various formulations, licensed by regulatory authorities worldwide. Their facilities meet cGMP standards, ensuring product quality.

• Dr. Reddy's Laboratories
  An Indian multinational, Dr. Reddy’s supplies naproxen formulations, including enteric-coated options, with approvals across multiple markets.

• Hetero Drugs
  Specialized in generic pharmaceuticals, Hetero manufactures remaining formulation variants of naproxen, including controlled-release and enteric-coated forms, supplying emerging markets.

3. Regional and Local Suppliers

In addition to global manufacturers, regional pharmaceutical companies produce localized versions of EC-NAPROSYN to meet market demands in specific countries.

• Zydus Cadila (India)
• Sun Pharmaceutical Industries (India)
• Aventis Pharma (Latin America)
• Pfizer (regional formulations)

Their production complies with regional regulatory standards, often supplying generics and branded medicines in local pharmacies.

Regulatory and Quality Considerations

Suppliers of EC-NAPROSYN must comply with rigorous quality assurance frameworks such as the FDA’s cGMP standards, EMA’s Good Manufacturing Practice, and equivalent regional regulations. The enteric coating’s integrity and dissolution profile are critical quality attributes, necessitating specialized manufacturing processes.

Global regulators frequently audit manufacturing sites to ensure compliance, and suppliers must provide robust stability data, bioequivalence evidence, and Good Distribution Practice (GDP) adherence for distribution approval.

Supply Chain Challenges

• Patent Expiry and Market Entry
  The patent for original naproxen formulations, including EC variants, has largely expired, facilitating entry by numerous generic suppliers. However, patent litigation and exclusivity rights in certain regions can influence supply availability.

• Manufacturing Capacity
  Meeting global demand requires significant manufacturing capacity, which becomes constrained during supply disruptions, regulatory delays, or raw material shortages.

• Regulatory Approvals and Variability
  Variability in regional approval processes complicates international supply chains. Suppliers must navigate diverse regulatory landscapes, affecting timelines and market availability.

Future Outlook

The supply landscape for EC-NAPROSYN will likely expand with emerging markets increasing pharmaceutical manufacturing capacity. Continuous advances in coating technology and formulation stability may lead to new suppliers entering the market. Moreover, strategic stockpiling and regional manufacturing hubs are expected to mitigate potential supply disruptions.

Manufacturers investing in quality enhancements, supply chain resilience, and regulatory compliance will maintain competitive positioning in the growing NSAID market.

Key Takeaways

• The primary suppliers of EC-NAPROSYN include original manufacturers like Bayer and Sanofi, alongside a broad spectrum of generic producers such as Aurobindo, Mylan, Torrent, and Dr. Reddy’s.

• Regional pharmaceutical companies supply localized formulations, diversifying supply sources and increasing market access.

• Regulatory compliance, manufacturing quality, and capacity are critical determinants of supply stability.

• Patent expirations have facilitated market entry for multiple generic suppliers, expanding availability but also increasing market competition.

• Supply chain disruptions remain a concern, emphasizing the importance of diversified sourcing and regional manufacturing strategies.

FAQs

1. Who are the leading global suppliers of EC-NAPROSYN?
Leading global suppliers include Bayer and Sanofi for branded formulations, with major generics manufacturers like Aurobindo, Mylan, Torrent, and Dr. Reddy’s providing extensive supply worldwide.

2. How does patent status influence supplier availability?
Patent expiration opens the market to numerous generics, increasing supplier diversity and supply options. Conversely, active patents or patent litigations can restrict generic entry and limit supplier options in specific markets.

3. What regulatory standards must suppliers meet?
Suppliers must adhere to cGMP (FDA), Good Manufacturing Practice (EMA), and local regulatory standards, ensuring product quality, safety, and efficacy, especially for formulations like EC-NAPROSYN where coating integrity is vital.

4. Are regional suppliers reliable sources for EC-NAPROSYN?
Yes, regional suppliers often provide reliable sources, especially in emerging markets, provided they meet international regulatory standards and quality controls.

5. What challenges might disrupt the supply of EC-NAPROSYN?
Challenges include raw material shortages, manufacturing capacity constraints, patent disputes, regulatory delays, and logistical issues, which can impact supply stability.

References

[1] U.S. Food and Drug Administration (FDA). Approved Drug Products. 2023.
[2] European Medicines Agency (EMA). Human Regulatory. 2023.
[3] Pfizer. Product Portfolio. 2023.
[4] Bayer AG. Corporate Reports. 2023.
[5] GlobalData. Pharmaceutical Market Outlook. 2023.